ERBB2 Mutation is an inclusion criterion in 21 clinical trials for malignant solid tumor, of which 16 are open and 5 are closed. Of the trials that contain ERBB2 Mutation and malignant solid tumor as inclusion criteria, 8 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), and 10 are phase 2 (9 open) [5].

ERBB2 Mutation is an inclusion criterion in 15 clinical trials for non-small cell lung carcinoma, of which 13 are open and 2 are closed. Of the trials that contain ERBB2 Mutation and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 9 are phase 2 (8 open) [5].

ERBB2 Mutation is an inclusion criterion in 9 clinical trials for breast carcinoma, of which 6 are open and 3 are closed. Of the trials that contain ERBB2 Mutation and breast carcinoma as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [5].

ERBB2 Mutation is an inclusion criterion in 5 clinical trials for urothelial carcinoma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (3 open) [5].

ERBB2 Mutation is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

ERBB2 Mutation is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 3 clinical trials for gastric carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 3 clinical trials for lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and lung carcinoma as inclusion criteria, 3 are phase 2 (3 open) [5].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for cervical carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and cervical carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for lung adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and lung adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for malignant uterine neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and malignant uterine neoplasm as inclusion criteria, 2 are phase 2 (2 open) [5].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 Mutation and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for non-squamous non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ERBB2 Mutation is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Mutation and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for biliary tract neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and biliary tract neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for ependymoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and ependymoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for malignant glioma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and malignant glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and medulloblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Mutation and rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for salivary gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and salivary gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ERBB2 Mutation is an inclusion criterion in 1 clinical trial for ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Mutation and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].